ACXP Profile
Acurx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical firm, is at the forefront of developing innovative antibiotics aimed at combating bacterial infections. The company's leading candidate, ibezapolstat, features a novel mechanism of action that targets the polymerase IIIC enzyme. Having successfully completed a Phase IIa clinical trial, ibezapolstat shows promise in treating patients with Clostridium difficile infections, a major cause of hospital-acquired infections and a significant public health challenge.
In addition to ibezapolstat, Acurx Pharmaceuticals is advancing the development of ACX-375C, a versatile antibiotic candidate intended for both oral and parenteral administration. This compound is designed to target a spectrum of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and penicillin-resistant Streptococcus pneumoniae. The development of ACX-375C underscores the company's commitment to addressing the growing issue of antibiotic resistance, which poses a serious threat to global health.
Acurx Pharmaceuticals' research and development efforts are supported by a robust pipeline of antibiotic candidates aimed at addressing unmet medical needs. The company's strategic focus on novel mechanisms of action and resistance-breaking therapies positions it uniquely within the biopharmaceutical landscape. Through rigorous clinical trials and innovative research, Acurx is dedicated to providing new solutions for patients suffering from severe bacterial infections.
Incorporated in 2017 and headquartered in Staten Island, New York, Acurx Pharmaceuticals leverages its expertise in antibiotic development to tackle some of the most pressing challenges in infectious disease treatment. The company's leadership team, composed of seasoned industry professionals, is committed to advancing its clinical programs and bringing new antibiotics to market. By prioritizing innovation and patient outcomes, Acurx Pharmaceuticals aims to make a significant impact on public health and the future of antibiotic therapy.
|
